NCT07372040 Add-on Diuretics in Acute Decompensated Heart Failure
| NCT ID | NCT07372040 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tanta University |
| Condition | Acute Decompensated Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2026-02-01 |
| Primary Completion | 2027-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 66 participants in total. It began in 2026-02-01 with a primary completion date of 2027-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.
Eligibility Criteria
Inclusion Criteria: 1. Male or female patients older than 18 years. 2. Hospital admission with clinical diagnosis of acute decompensated heart failure with at least one clinical sign of volume overload (e.g. edema, ascites confirmed by echography or pleural effusion confirmed by chest X-ray or echography). Exclusion Criteria: 1. Type 1 diabetes. 2. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 mL/min per 1.73 m² or end-stage kidney failure with the need for chronic dialysis treatment. 3. A systolic blood pressure of less than 90 mmHg. 4. Cardiogenic shock. 5. Receipt of acetazolamide maintenance therapy. 6. Receipt of an SGLT2 inhibitor, thiazide, or thiazide-like diuretic in the 48 hrs before randomization. 7. Any cause of heart failure leading to decompensation that will need urgent management (eg, acute coronary syndrome, unstable arrhythmias, acute pulmonary embolism). 8. Pregnant or breastfeeding women. 9. Moderate to severe anemia.
Contact & Investigator
Dalia A Gomaa, MSc in clinical pharmacy
PRINCIPAL INVESTIGATOR
Tanta University
Frequently Asked Questions
Who can join the NCT07372040 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Decompensated Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07372040 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07372040 currently recruiting?
Yes, NCT07372040 is actively recruiting participants. Contact the research team at dalia_gomaa@pharm.tanta.edu.eg for enrollment information.
Where is the NCT07372040 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07372040 clinical trial?
NCT07372040 is sponsored by Tanta University. The principal investigator is Dalia A Gomaa, MSc in clinical pharmacy at Tanta University. The trial plans to enroll 66 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.